Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bertrand Cariou

Showing results (1-10 of 311) with videos related to

Pageof 32
Sort By:
La Revue Du Praticien|December 5, 2018
[Dyslipidemia and statins role]Bertrand Cariou
La Revue Du Praticien|December 5, 2018
[What is the place of statins in the treatment of diabetes?]Bertrand Cariou
La Revue Du Praticien|December 5, 2018
[Adverse effects of statins]Bertrand Cariou
La Revue Du Praticien|December 5, 2018
[Cardiovascular risk: what is the role of HDL cholesterol?]Bertrand Cariou
La Revue Du Praticien|January 12, 2016
[A YOUNG MAN WHOSE LDL-CHOLESTEROL IS GREATER THAN 1.9 G/L]Bertrand Cariou
Diabetes, Obesity & Metabolism|January 11, 2022
The metabolic triad of non-alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatmentBertrand Cariou
Journal of Hepatology|May 26, 2024
Reply to: "Primary hypobetalipoproteinemia as a risk factor for liver complications"Matthieu Wargny, Bertrand Cariou
Atherosclerosis|December 1, 2019
EGF-A peptides: A promising strategy for PCSK9 inhibitionBertrand Cariou, Wieneke Dijk
Diabetes, Obesity & Metabolism|April 20, 2019
Efficacy and safety of proprotein convertase subtilisin/kexin 9 inhibitors in people with diabetes and dyslipidaemiaWieneke Dijk, Bertrand Cariou
Trends in Cardiovascular Medicine|July 6, 2020
Editorial commentary: Lp(a) and calcific aortic valve stenosis: Direct LPA targeting or PCSK9-Lowering therapy?Romain Capoulade, Bertrand Cariou
Pageof 32

Showing results (1-10 of 311) with videos related to

Sort By:
Pageof 32
La Revue Du Praticien|December 5, 2018
[Dyslipidemia and statins role]Bertrand Cariou
La Revue Du Praticien|December 5, 2018
[What is the place of statins in the treatment of diabetes?]Bertrand Cariou
La Revue Du Praticien|December 5, 2018
[Adverse effects of statins]Bertrand Cariou
La Revue Du Praticien|December 5, 2018
[Cardiovascular risk: what is the role of HDL cholesterol?]Bertrand Cariou
La Revue Du Praticien|January 12, 2016
[A YOUNG MAN WHOSE LDL-CHOLESTEROL IS GREATER THAN 1.9 G/L]Bertrand Cariou
Diabetes, Obesity & Metabolism|January 11, 2022
The metabolic triad of non-alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatmentBertrand Cariou
Journal of Hepatology|May 26, 2024
Reply to: "Primary hypobetalipoproteinemia as a risk factor for liver complications"Matthieu Wargny, Bertrand Cariou
Atherosclerosis|December 1, 2019
EGF-A peptides: A promising strategy for PCSK9 inhibitionBertrand Cariou, Wieneke Dijk
Diabetes, Obesity & Metabolism|April 20, 2019
Efficacy and safety of proprotein convertase subtilisin/kexin 9 inhibitors in people with diabetes and dyslipidaemiaWieneke Dijk, Bertrand Cariou
Trends in Cardiovascular Medicine|July 6, 2020
Editorial commentary: Lp(a) and calcific aortic valve stenosis: Direct LPA targeting or PCSK9-Lowering therapy?Romain Capoulade, Bertrand Cariou
Pageof 32